other material
confidence high
sentiment neutral
materiality 0.55
Lineage Cell Therapeutics files prospectus supplement for up to $60M ATM offering
Lineage Cell Therapeutics, Inc.
- Offers up to $60,000,000 of common shares in at-the-market offering through B. Riley Securities.
- Prior sales under the same shelf registration total $22,583,664 in aggregate gross proceeds.
- Prospectus supplement dated March 11, 2026 supplements shelf registration effective May 14, 2024.